Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 71

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 71
---
 Shares

An active, liquid and orderly trading market for our Ordinary Shares may not develop, which may inhibit the ability of our shareholders to sell Ordinary Shares following this offering.

Prior to this offering there
has been no public market for our Ordinary Shares. An active, liquid or orderly trading market in our Ordinary Shares may not develop
upon completion of this offering, or if it does develop, it may not be sustained. The lack of an active market may impair your ability
to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also
reduce the fair market value of your shares. An inactive market may also impair our ability to raise capital in the future by selling
shares and may impair our ability to acquire other companies by using our shares as consideration.

The market price of our Ordinary Shares may be volatile, which could result in substantial losses for investors purchasing shares in this offering.

The initial public offering
price for the Ordinary Shares will be determined through negotiations with the underwriters. The initial public offering price may differ
from the market price of our Ordinary Shares after the offering. As a result, you may not be able to sell your Ordinary Shares at or above
the initial public offering price. Some of the factors that may cause the market price of our Ordinary Shares to fluctuate include:

| ● | delays or setbacks in the ongoing commercialization of GelrinC; |

| ● | the success of existing or new competitive products or technologies; |

| ● | regulatory or legal developments in the United States and other countries; |

| ● | developments or disputes concerning patent applications, issued patents or other proprietary rights; |

| ● | the recruitment or departure of key personnel; |

| ● | the commencement of litigation; |

<div align='center'>46</div>

| ● | actual or anticipated changes in estimates as to financial results; |

| ● | announcement or expectation of additional financing efforts; |

| ● | sales of our Ordinary Shares by us, our insiders or other shareholders; |

| ● | expiration of market standoff or lock-up agreements; |

| ● | variations in our financial results or those of companies that are perceived to be similar to us; |

| ● | changes in estimates or recommendations by securities analysts, if any, that cover our shares; |

| ● | changes in the structure of health care payment systems; |

| ● | market conditions in the medical device sectors; |

| ● | the seasonality of our business; |

| ●